Year : 2020 | Volume
: 4 | Issue : 3 | Page : 421--426
Serum Beclin 1 in HCC and correlation with MDA as an oxidant
Zeinab A Mohammed1, Fatma A.K Attia1, Fatma M El-Senosy1, Eman R Younes2, Fadila M Elsayed3
1 Department of Internal Medicine, Al Azhar University, Cairo, Egypt
2 Department of Department of Medical Biochemistry, Medical Division National Research Center, Cairo, Egypt
3 Department of Diagnostic Radiology, Faculty of Medicine for Girls, Al Azhar University, Cairo, Egypt
Background Hepatocellular carcinoma (HCC) is the second most lethal cancer worldwide with persistently increasing mortality in Europe, North/South America, and Africa, in contrast to the decreasing trend in East Asia. Cirrhosis was estimated to cause more than 1.2 million deaths (2% of global deaths) in 2013, an increase of 47% since 1990.
Aim The aim was to assess serum Beclin 1 as a biomarker in HCC regarding its role in pathogenesis and its correlation with serum malondialdehyde (MDA) as an oxidant.
Patients and methods This is a case–control study conducted on 60 participants who were divided into two groups: group 1 included 30 patients with HCC, comprising 26 males and four females, with ages ranging from 55 to 75 years. Group II included 30 healthy participants as a control group, comprising 21 males and nine females, with ages ranging from 25 to 42 years. Routine laboratory investigations were done, and serum Beclin 1 and serum MDA were measured in both groups. Abdominal ultrasonography and triphasic computed tomography were done for the patient group. All patients were recruited from Internal Medicine Department (Al-Mansoura University Hospital) after obtaining oral consent to be participated in the study.
Results There was a highly significant decrease in serum Beclin 1 levels (<0.001) in patients with HCC when compared with the control group. The significant association between Beclin 1 and HCC suggests that low Beclin 1 levels may play an important role in the development of HCC. Moreover, there was a statistically significant increased serum MDA level (>0.001) in patients with HCC as compared with control group. There was a positive correlation between Beclin 1 and BMI in the patient group (r=0.42 and P=0.02), a negative correlation between MDA and red blood cells in the patient group (r=−0.40 and P=0.03), and a positive correlation between MDA and aspartate transaminase in the patient group (r=0.41 and P=0.02).
Conclusion Findings of our study have demonstrated that serum Beclin 1 and MDA levels could be used as possible predictors of pathogenesis of HCC.
MBBCH Zeinab A Mohammed
Department of Internal Medicine, Al Azhar University, Faculty of Medicine (For Girls), AL-Azhar University, Al_Mansoura, Al Dakhlia, 35511
|How to cite this article:|
Mohammed ZA, Attia FA, El-Senosy FM, Younes ER, Elsayed FM. Serum Beclin 1 in HCC and correlation with MDA as an oxidant.Sci J Al-Azhar Med Fac Girls 2020;4:421-426
|How to cite this URL:|
Mohammed ZA, Attia FA, El-Senosy FM, Younes ER, Elsayed FM. Serum Beclin 1 in HCC and correlation with MDA as an oxidant. Sci J Al-Azhar Med Fac Girls [serial online] 2020 [cited 2020 Nov 27 ];4:421-426
Available from: http://www.sjamf.eg.net/article.asp?issn=1110-2381;year=2020;volume=4;issue=3;spage=421;epage=426;aulast=Mohammed;type=0